Lophius Biosciences
Founded Year
2008Stage
Acquired | AcquiredTotal Raised
$23.84MAbout Lophius Biosciences
Lophius Biosciences is a privately-held biotech company focused on the development and marketing of T cell-based research tools, contract research solutions and diagnostics for functional assessment of pathogen/disease-reactive T cells. The company's flagship product is T-Track CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus (CMV) seropositive transplant patients who undergo an immunosuppressive therapy. On March 9th, 2021, Lophius Biosciences was acquired by Mikrogen. The terms of the transaction were not disclosed.
Missing: Lophius Biosciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Lophius Biosciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Lophius Biosciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lophius Biosciences is included in 4 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Health IT
7,901 items
Lophius Biosciences Patents
Lophius Biosciences has filed 8 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Human proteins
- Immune system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/8/2016 | 12/26/2017 | Immune system, Immunology, Clusters of differentiation, Transcription factors, Autoimmune diseases | Grant |
Application Date | 9/8/2016 |
|---|---|
Grant Date | 12/26/2017 |
Title | |
Related Topics | Immune system, Immunology, Clusters of differentiation, Transcription factors, Autoimmune diseases |
Status | Grant |
Latest Lophius Biosciences News
Mar 9, 2021
Mikrogen Diagnostik erwirbt Lophius Biosciences ) Das Diagnostikunternehmen Mikrogen GmbH aus Neuried erwirbt die Lophius Biosciences GmbH aus dem BioPark Regensburg, um in den Zukunftsmarkt für T-Zell-basierte Tests einzusteigen. Die Immundiagnostik spielt eine große Rolle in den Bereichen Transplantation sowie Infektions- und Autoimmunerkrankungen. Die 2002 aus der Universität Regensburg heraus gegründete Lophius Biosciences GmbH wurde von Mikrogen Diagnostik erworben. Seit 1989 produziert die Mikrogen GmbH im oberbayerischen Neuried mit 150 Mitarbeitern Antigene für die klinische Diagnostik. Der globale Anbieter von Systemlösungen für die medizinische Labordiagnostik bietet vielfältige serologische und molekulardiagnostische Systeme an. Der Schwerpunkt liegt auf der direkten und indirekten Detektion von bakteriellen, viralen und parasitären Infektionen sowie auf Autoimmun- und Krebserkrankungen. Die Kombination des Know-hows in Diagnostik und Automation von Mikrogen mit der Lophius Technologie zur pathogenspezifischen Immunstimulation, wird neuartige diagnostische Lösungen für Infektionskrankheiten ermöglichen und das Mikrogen-Portfolio ergänzen. Mikrogen wird den Betrieb erweitern, indem sie das gesamte Lophius-Team und die Lophius-Labore im BioPark Regensburg übernimmt. In Zukunft werden die von Lophius entwickelten In-vitro-Diagnosekits von Mikrogen vermarktet. „Wir freuen uns, unsere neuen Kollegen von Lophius an Bord begrüßen zu dürfen. Wir glauben, dass die Zusammenführung der beiden Teams und ihres komplementären Fachwissens unsere Innovationskraft bei der Entwicklung neuer diagnostischer Lösungen beschleunigen wird“, sagte Dr. Erwin Soutschek, CEO & Geschäftsführer der Mikrogen GmbH. Weitere Informationen unter: 11:00
Lophius Biosciences Frequently Asked Questions (FAQ)
When was Lophius Biosciences founded?
Lophius Biosciences was founded in 2008.
Where is Lophius Biosciences's headquarters?
Lophius Biosciences's headquarters is located at Am BioPark 13, Regensburg.
What is Lophius Biosciences's latest funding round?
Lophius Biosciences's latest funding round is Acquired.
How much did Lophius Biosciences raise?
Lophius Biosciences raised a total of $23.84M.
Who are the investors of Lophius Biosciences?
Investors of Lophius Biosciences include Mikrogen, Bayern Kapital, VRD GmbH, Wolf Biotech, WIC GmbH and 8 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.